Related Experiment Video
Updated: Aug 18, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Inflammatory biomarkers and statins
Luis Miguel Blanco-Colio1, José Tuñón, José Luis Martín-Ventura
1Vascular Research Lab, Department of Cardiology, Fundacion Jimenez Diaz, Autonoma University, Madrid, Spain.
Insights
Atherosclerosis is an inflammatory disease. This review explores inflammatory markers like C-reactive protein (CRP) and their modulation by statins (HMG-CoA reductase inhibitors) for cardiovascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Inflammation Research
- Pharmacology
Background:
- Atherosclerosis is increasingly recognized as an inflammatory disorder.
- Elevated inflammatory molecules are observed in individuals at high risk for acute coronary events.
- Understanding these markers aids in disease pathogenesis and therapeutic strategies.
Purpose of the Study:
- To review current inflammatory markers used in assessing cardiovascular risk.
- To analyze the therapeutic modulation of these markers by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins).
- To discuss the future potential of novel biomarkers in cardiovascular disease prevention and treatment.
Main Methods:
- Literature review of inflammatory markers in atherosclerosis.
- Analysis of studies investigating the effects of HMG-CoA reductase inhibitors on inflammatory markers.
- Exploration of emerging technologies for biomarker discovery.
Main Results:
- C-reactive protein (CRP), CD40 ligand, adhesion molecules, and chemokines are key inflammatory markers.
- HMG-CoA reductase inhibitors demonstrate modulation of these inflammatory markers.
- Current therapeutic interventions show promise in managing inflammatory aspects of atherosclerosis.
Conclusions:
- Inflammatory markers play a crucial role in understanding atherosclerosis.
- Statins offer a therapeutic approach to modulate inflammation in cardiovascular disease.
- Future advancements in biomarker discovery will enhance cardiovascular disease prevention and treatment strategies.
Abstract:
The concept of atherosclerosis as an inflammatory disorder has led to the exploration of new pathogeneses of this disease. In this regard, the levels of several inflammatory molecules are frequently increased in subjects at high risk of developing an acute coronary event. With a simple analysis we can characterize the circulating levels of a marker and its therapeutic modulation with various drugs. In this review we have analyzed different inflammatory markers currently used, such as C-reactive protein (CRP), CD40 ligand, adhesion molecules and chemokines, and their possible modulation by therapeutic intervention with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Moreover, in the future, new technologies will allow us to discover new markers, or sets of them, that could indicate the direction to be taken in the prevention and treatment of cardiovascular diseases.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:38Inflammation